Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation

Toxicology and Applied Pharmacology

Volumn 281, Issue 1, 2014, Pages 39-47

  Yagi, Yukihiro ^a,b   Nakamura, Yuji ^a   Kitahara, Ken ^a   Harada, Takuma ^a   Kato, Kazuhiko ^b   Ninomiya, Tomohisa ^b   Cao, Xin ^a   Ohara, Hiroshi ^a   Izumi Nakaseko, Hiroko ^a   Suzuki, Kokichi ^b   Ando, Kentaro ^a   Sugiyama, Atsushi ^a  

^a TOHO UNIVERSITY   (Japan)

^b MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

Atrioventricular conduction block; Fingolimod; Guinea pig; QT interval prolongation; Siponimod; Sphingosine 1 phosphate

Indexed keywords

FINGOLIMOD; POTASSIUM CHANNEL HERG; SIPONIMOD; IMMUNOSUPPRESSIVE AGENT; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; ATRIOVENTRICULAR BLOCK; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MEGADOSE; ELECTROCARDIOGRAM; GUINEA PIG MODEL; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART VENTRICLE PACING; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PR INTERVAL; QT PROLONGATION; ANIMAL; BRUGADA SYNDROME; CHEMICALLY INDUCED; DRUG EFFECTS; GUINEA PIG; HEART MUSCLE CONDUCTION SYSTEM; HEK293 CELL LINE; LONG QT SYNDROME; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ATRIOVENTRICULAR BLOCK; BRUGADA SYNDROME; FINGOLIMOD HYDROCHLORIDE; GUINEA PIGS; HEART CONDUCTION SYSTEM; HEK293 CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG QT SYNDROME; MALE; RECEPTORS, LYSOSPHINGOLIPID;

EID: 84908345883     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.09.006     Document Type: Article

References (35)

1. Albert R., Hinterding K., Brinkmann V., Guerini D., Müller-Hartwieg C., Knecht H., Simeon C., Streiff M., Wagner T., Welzenbach K., Zécri F., Zollinger M., Cooke N., Francotte E. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J. Med. Chem. 2005, 48:5373-5377.
2. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., Pelletier J., Capra R., Gallo P., Izquierdo G., Tiel-Wilck K., de Vera A., Jin J., Stites T., Wu S., Aradhye S., Kappos L., TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:402-415.
3. Comi G., O'Connor P., Montalban X., Antel J., Radue E.W., Karlsson G., Pohlmann H., Aradhye S., Kappos L., FTY720D2201 Study Group Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult. Scler. 2010, 16:197-207.
4. Drici M.D., Diochot S., Terrenoire C., Romey G., Lazdunski M. The bee venom peptide tertiapin underlines the role of I(KACh) in acetylcholine-induced atrioventricular blocks. Br. J. Pharmacol. 2000, 131:569-577.
5. European Medicines Agency Assessment report Gilenya, Procedure No. EMEA/H/C/2202 Available at, (accessed 15 November 2013). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf.
6. Food and Drug Administration ICH Harmonised Tripartite Guideline, S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals: US Department of Health and Human Services Available at, (accessed 15 November 2013). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm074963.pdf.
7. Food and Drug Administration Fingolimod (NDA 22-527) Background Package Available at, (accessed 15 November 2013). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm214670.pdf.
8. Forrest M., Sun S.Y., Hajdu R., Bergstrom J., Card D., Doherty G., Hale J., Keohane C., Meyers C., Milligan J., Mills S., Nomura N., Rosen H., Rosenbach M., Shei G.J., Singer I.I., Tian M., West S., White V., Xie J., Proia R.L., Mandala S. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther. 2004, 309:758-768.
9. Gergely P., Nuesslein-Hildesheim B., Guerini D., Brinkmann V., Traebert M., Bruns C., Pan S., Gray N.S., Hinterding K., Cooke N.G., Groenewegen A., Vitaliti A., Sing T., Luttringer O., Yang J., Gardin A., Wang N., Crumb W.J., Saltzman M., Rosenberg M., Wallström E. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br. J. Pharmacol. 2012, 167:1035-1047.
10. 1 agonist that does not require S1P-like headgroup interactions. Mol. Pharmacol. 2008, 74:1308-1318.
11. Hamill O.P., Marty A., Neher E., Sakmann B., Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981, 391:85-100.
12. 5 (Edg-8): structure-activity relationship of sphingosine1-phosphate receptors. Biochemistry 2001, 40:14053-14060.
13. Jeffrey O., Douglas P.Z. Specific Arrhythmias: Diagnosis and Treatment. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine 2012, vol. 1:818-822. Elsevier Inc., PA, (chapter 39). 9th edition. O.B. Robert, L.M. Douglas, P.Z. Douglas, L. Peter (Eds.).
14. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., Selmaj K., Agoropoulou C., Leyk M., Zhang-Auberson L., Burtin P., FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
15. Kilkenny C., Browne W., Cuthill I.C., Emerson M., Altman D.G. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br. J. Pharmacol. 2010, 160:1577-1579.
16. Kise H., Nakamura Y., Hoshiai M., Sugiyama H., Sugita K., Sugiyama A. Cardiac and haemodynamic effects of tacrolimus in the halothane-anaesthetized dog. Basic Clin. Pharmacol. Toxicol. 2010, 106:288-295.
17. KACh. Am. J. Transplant. 2005, 5:529-536.
18. Landeen L.K., Dederko D.A., Kondo C.S., Hu B.S., Aroonsakool N., Haga J.H., Giles W.R. Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H736-H749.
19. Legangneux E., Gardin A., Johns D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br. J. Clin. Pharmacol. 2013, 75:831-841.
20. McGrath J.C., Drummond G.B., McLachlan E.M., Kilkenny C., Wainwright C.L. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br. J. Pharmacol. 2010, 160:1573-1576.
21. Mullershausen F., Zecri F., Cetin C., Billich A., Guerini D., Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat. Chem. Biol. 2009, 5:428-434.
22. Novartis, 2012. Full Prescribing Information: Gilenya (fingolimod) capsules Available at, (accessed 15 November 2013). http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf.
23. 5 inhibits oligodendrocyte progenitor migration. FASEB J. 2007, 21:1503-1514.
24. + currents. Cardiovasc. Res. 2006, 70:88-96.
25. Kr blockade: comparison with urethane anesthesia. J. Pharmacol. Sci. 2005, 99:185-190.
26. Sakaguchi Y., Takahara A., Nakamura Y., Akie Y., Sugiyama A. Halothane-anaesthetized, closed-chest, guinea-pig model for assessment of drug-induced QT-interval prolongation. Basic Clin. Pharmacol. Toxicol. 2009, 104:43-48.
27. Sanna M.G., Liao J., Jo E., Alfonso C., Ahn M.Y., Peterson M.S., Webb B., Lefebvre S., Chun J., Gray N., Rosen H. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 2004, 279:13839-13848.
28. Schuchardt M., Tölle M., Prüfer J., van der Giet M. Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system. Br. J. Pharmacol. 2011, 163:1140-1162.
29. Selmaj K., Li D.K., Hartung H.P., Hemmer B., Kappos L., Freedman M.S., Stüve O., Rieckmann P., Montalban X., Ziemssen T., Auberson L.Z., Pohlmann H., Mercier F., Dahlke F., Wallström E. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013, 12:756-767.
30. Shimizu H., Takahashi M., Kaneko T., Murakami T., Hakamata Y., Kudou S., Kishi T., Fukuchi K., Iwanami S., Kuriyama K., Yasue T., Enosawa S., Matsumoto K., Takeyoshi I., Morishita Y., Kobayashi E. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005, 111:222-229.
31. Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br. J. Pharmacol. 2008, 154:1528-1537.
32. Sugiyama A., McKnite S., Wiegn P., Lurie K.G. Measurement of cAMP in the cardiac conduction system. J. Histochem. Cytochem. 1995, 43:601-605.
33. Sugiyama A., Aye N.N., Katahira S., Saitoh M., Hagihara A., Matsubara Y., Hashimoto K. Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol. Appl. Pharmacol. 1997, 143:89-95.
34. Tamargo J., Caballero R., Gómez R., Valenzuela C., Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc. Res. 2004, 62:9-33.
35. Yoshida H., Sugiyama A., Satoh Y., Ishida Y., Kugiyama K., Hashimoto K. Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model. Circ. J. 2002, 66:857-862.